Oculogica

Executive Summary

Oculogica is a digital health company that has developed EyeBOX, the first FDA-cleared, non-invasive device for objective diagnosis of concussion by measuring eye movement abnormalities. The device provides results in under four minutes without requiring a baseline, making it suitable for use in diverse clinical settings such as sports medicine, emergency departments, and veteran care. Founded in 2013 and headquartered in New York, Oculogica addresses a critical unmet need in concussion diagnosis, where current methods rely on subjective assessments. With increasing awareness of concussion risks in sports and military contexts, the company's technology offers a unique value proposition. However, the company remains private with limited disclosed funding, and its commercial traction is unclear. The concussion diagnostics market is competitive, with players like ImPACT and BrainScope, but EyeBOX's baseline-free design and speed could differentiate it. Overall, Oculogica holds promise in a growing market but faces commercialization challenges.

Upcoming Catalysts (preview)

• Q4 2026Publication of pivotal clinical study results validating EyeBOX in pediatric populations70% success
• Q1 2027Strategic partnership with a major sports league (e.g., NFL, NCAA) for sideline concussion testing50% success
• Q2 2027FDA 510(k) clearance for expanded indications, including mild traumatic brain injury (mTBI) beyond concussion60% success